Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cortisone acetate
Drug ID BADD_D00533
Description Cortisone acetate was first isolate in 1935 and became more widely researched in 1949.[A226295] Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and gastrointestinal diseases and disorders.[A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.[L15107]
Indications and Usage For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders.
Marketing Status Prescription; Discontinued
ATC Code H02AB10; S01BA03
DrugBank ID DB01380
KEGG ID D00973
MeSH ID D003348
PubChem ID 5745
TTD Drug ID D0X4RS
NDC Product Code 0220-1554; 0143-1202; 0220-1553; 0143-9700; 64958-0025; 49452-2321; 0220-1550
Synonyms Cortisone | Cortisone Acetate | 17-Hydroxy-3,11,20-trioxopregn-4-en-21-yl acetate | Cortone Acetate | Adreson
Chemical Information
Molecular Formula C23H30O6
CAS Registry Number 50-04-4
SMILES CC(=O)OCC(=O)C1(CCC2C1(CC(=O)C3C2CCC4=CC(=O)CCC34C)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypoaesthesia17.02.06.0230.021466%Not Available
Hypokalaemic syndrome14.05.03.003--Not Available
Impaired healing08.03.02.001--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Intracranial pressure increased17.07.02.002--Not Available
Large intestine perforation12.02.03.005; 07.04.06.005--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.010733%
Malaise08.01.01.003--
Menstrual disorder21.01.01.004--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial rupture02.04.02.002; 12.01.11.002--Not Available
Nausea07.01.07.001--
Nitrogen balance negative13.13.01.010--Not Available
Osteonecrosis24.04.05.004; 15.02.04.007--
Pain08.01.08.0040.010733%
Pancreatitis07.18.01.001--
Papilloedema24.03.07.001; 17.07.02.004; 06.09.02.002--
Paranoia19.05.01.0050.016100%Not Available
Pathological fracture16.32.03.007; 15.08.02.008; 12.04.02.006--Not Available
Peptic ulcer07.04.07.001--Not Available
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Pneumonia22.07.01.003; 11.01.09.0030.010733%Not Available
Polyneuropathy17.09.03.0120.021466%Not Available
Psoriasis23.03.14.002; 10.02.01.0360.026833%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.0010.021466%Not Available
Pyrexia08.05.02.0030.021466%
Rash23.03.13.0010.010733%Not Available
Schizophrenia19.03.04.0010.016100%Not Available
Secondary adrenocortical insufficiency05.01.02.003; 14.11.01.014--Not Available
Seizure17.12.03.001--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages